The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
V | Various | |
2
|
V10 | Therapeutic radiopharmaceuticals | |
3
|
V10X | Other therapeutic radiopharmaceuticals | |
4
|
V10XX | Various therapeutic radiopharmaceuticals |
| Code | Title | |
|---|---|---|
| V10XX01 | Sodium phosphate (32P) | |
| V10XX02 | Ibritumomab tiuxetan [90Y] | |
| V10XX03 | ||
| V10XX04 | ||
| V10XX05 |
| Active Ingredient |
|---|
|
Lutetium (177Lu) oxodotreotide has a high affinity for subtype 2 somatostatin receptors (sst2). It binds to malignant cells which overexpress sst2 receptors. Lutetium-177 (177Lu) is a βemitting radionuclide with a maximum penetration range in tissue of 2.2 mm (mean penetration range of 0.67 mm), which is sufficient to kill targeted tumour cells with a limited effect on neighbouring normal cells. |
|
|
|
Radium-223 dichloride mimics calcium and selectively targets bone, specifically areas of bone metastases, by forming complexes with the bone mineral hydroxyapatite. Radium-223 dichloride monotherapy or in combination with luteinising hormone releasing hormone (LHRH) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC). |
| Document | Type | Information Source | |
|---|---|---|---|
| LUTATHERA Solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| LUTATHERA Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| PLUVICTO Solution for injection/infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| XOFIGO Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| ZEVALIN Kit for radiopharmaceutical preparations for infusion | MPI, EU: SmPC | European Medicines Agency (EU) |